Previous Columns

Sleep-timing regularity outperforms sleep duration as an all-cause mortality predictor in this week's large-cohort data, while the APAC protocol clinic market prices epigenetic precision on a different variable.

The grey-market peptide stack prices irisin-pathway exposure without Phase 1 data; two studies this week show resistance training produces the same molecule with measurable clinical endpoints.

The influencer-physician model has sold clinical authority without clinical infrastructure, and the DIY peptide injection surge is the market clearing that price.

A Nature study linked curtailed sleep to DNA methylation age acceleration; APAC protocol capital is priced on monitoring that signal rather than treating the cause.

The APAC longevity capital stack prices lifestyle optimization protocols; the clinical signals this week measured epigenetic aging rates and early-life microbiome windows that no adult optimization protocol addresses.

The week's strongest aging science locates its determinants in sleep architecture and early-life microbiome, two variables that the adult behavioral-optimization market cannot move at the price it is charging.

The rapamycin disappointment does not kill the longevity capital thesis; it forces a read on which version of that thesis APAC money was actually holding.